Novartis

Novartis alums Jimenez, Fishman unveil their next act: Aditum Bio
Fierce Biotech
Mon, 11/2/20 - 10:18 am
Joe Jimenez
Novartis
Aditum Bio
biotech
funding
Novartis sharpens focus on vision-restoring gene therapy with $150M Vedere buyout
Fierce Biotech
Thu, 10/29/20 - 11:59 am
Novartis
Vedere Bio
gene therapy
vision loss
Novartis taps Molecular Partners for a new way to defeat COVID-19
Fierce Biotech
Wed, 10/28/20 - 10:33 am
Novartis
Molecular Partners
antivirals
MP0420
MP0423
COVID-19
Novartis CEO thinks 2nd health lockdown unlikely, as Q3 sales stabilize
Pharmaforum
Tue, 10/27/20 - 10:36 am
Novartis
earnings
COVID-19
pandemic
Novartis' Most Advanced Kidney Compound Shows Promise in C3G
BioSpace
Mon, 10/26/20 - 11:11 am
Novartis
ASN
C3G
clinical trials
iptacopan
Novartis launches digital health hub in Canada
Pharmaforum
Fri, 10/23/20 - 10:51 am
Novartis
Canada
innovation
digital health
Years after a major trial setback, Novartis switches gears with SMA drug. This time they're trying it for Huntington's
Endpoints
Wed, 10/21/20 - 11:43 pm
Novartis
SMA
branaplam
Huntington's disease
Novartis bet $6B on the idea — now Versant, venBio have $45M to birth a platform play for radiopharmaceuticals
Endpoints
Wed, 10/14/20 - 10:51 am
Versant Ventures
PSMA-617
radiopharmaceuticals
prostate cancer
Novartis
Rayze Bio
venBio
Pandemic speeds up Novartis’ transformation
MedCity News
Wed, 10/14/20 - 10:22 am
Novartis
digital health
artificial intelligence
data
HLTH
pandemic
COVID-19
Novartis vets get $35M to pluck one of the pharma giant’s abandoned drugs off the shelf and put it back into a clinical trial
Endpoints
Mon, 10/12/20 - 10:10 am
Novartis
KRP-203
Kyorin
Priothera Limited
AML
Pharmacquired: Splashy deals belie a shallow pool of heart drugs left to acquire
BioPharma Dive
Thu, 10/8/20 - 11:16 pm
M&A
cardiology
Bristol-Myers Squibb
MyoKardia
Novartis
The Medicines Company
Occupied with immunology and cancer, Merck KGaA hands off osteoarthritis drug to Novartis for €50M cash
Endpoints
Tue, 10/6/20 - 11:26 pm
Merck
KGaA
Novartis
sprifermin
osteoarthritis
From no drugs to 3: Patients with spinal muscular atrophy now face hard choices
BioPharma Dive
Mon, 10/5/20 - 11:39 pm
SMA
spinal muscular atrophy
Novartis
Zolgensma
Spinraza
Roche
Evrysdi
Amgen Highlights Long-Term Aimovig Data for Episodic Migraine
BioSpace
Mon, 10/5/20 - 11:43 am
Amgen
Novartis
Aimovig
migraines
episodic migraines
Novartis, Amgen and Mallinckrodt used aggressive price hikes to meet sales goals, congressional probe finds
Fierce Pharma
Thu, 10/1/20 - 11:29 am
congress
drug pricing
Novartis
Amgen
Mallinckrodt
Novartis sells $2.1B in bonds to increase access to its drugs in disadvantaged countries
Beckers Hospital Review
Thu, 09/24/20 - 10:28 am
Novartis
bonds
access
FDA sets back Novartis plans to expand use of SMA gene therapy
BioPharma Dive
Wed, 09/23/20 - 10:39 am
Novartis
SMA
gene therapy
Zolgensma
clinical trials
FDA
Bristol, Amgen, Teva CEOs among execs to testify at House drug pricing hearings next week
Fierce Pharma
Tue, 09/22/20 - 10:21 pm
drug pricing
regulatory
Celgene
Bristol-Myers Squibb
Teva Pharmaceutical
Amgen
Novartis
Mallinckrodt
AbbVie
US Congress
OptumRx's 3 recently approved drugs to watch
Beckers Hospital Review
Tue, 09/22/20 - 10:15 pm
FDA
Kite Pharma
Tecartus
Novartis
Kesimpta
MorphoSys
Monjuvi
OptumRx
Sandoz working to overcome barriers to greater biosimilars uptake in US
Biopharma Reporter
Mon, 09/21/20 - 10:55 am
Sandoz
biosimilars
Novartis

Pages